Resource Hub
VIRTUAL TOUR
CONTACT US
Our Company
About Us
Our Journey
Leadership
Scientific and BD Team
Aragen Advantage
Global Locations
Media & Events
Recognitions
Services
Small Molecules
Discovery
Integrated Drug Discovery
Chemistry
Biology
BioSafety
Development & Manufacturing
Drug Substance
Drug Product
Analytical Development
Performance Chemicals
Custom Chemical Synthesis
Commercial Manufacturing
Large Molecules (Biologics)
Discovery
Integrated Discovery
Biology
Molecular Biology
Antibody Discovery
Protein Sciences
Cell Line Development
Development & Manufacturing
Process Research & Development
Bioproduction
Developability & Analytics
GMP Manufacturing
Investors
Annual Reports and Annual Returns
Corporate Governance
Our Responsibility
Digital & AI (DnA)
EHS & Sustainability
Strategic Supply Chain Management
Quality
IP Protection & Data Security
Employee Welfare
Corporate Social Responsibility
Corporate Governance
Careers
Working at Aragen
Career Opportunities
Meet Our People
Caution Notice
Virtual Tour
Resources
Close Search
Search
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
GET IN TOUCH
Back to Resources
Whitepapers
Filter by Science
All
All
Analytical
Biologics
Biology
Chemistry
Development
Drug Substance
Formulations BU
Manufacturing
PCET
SAS/Toxicology
Translational PK/PD in Oncology: Linking Tumor Exposure to Clinical Response
Analytical Challenges in Scale-Up: Lab to Commercial Methods
Standalone GMP Analytics in Outsourced Models: Driving Flexibility and Speed
De-Risking Biologics Technology Transfer: A Process-First Approach to Seamless Site Transitions
Root Causes of API Scale-up Failures: How to Avoid Them
Particle Engineering Meets Formulation: Why Integration Matters
Cyclic Peptides in Drug Discovery: Enabling Better Design
Phase-Appropriate CMC Strategies for Complex Small Molecules: Integrating Drug Substance and Drug Product to Avoid Late-Stage Surprises
Integrated In vivo Oncology Studies for Predictive Preclinical Efficacy Outcomes
GLP-Compliant Toxicology Studies: The Cornerstone of Vaccine Safety and Regulatory Approval
High-Content Screening: Accelerating Smarter Drug Discovery Decisions
Surviving Early Development: Why Integrated DS–DP Programs Reduce CMC Risk
Zero 483 Quality Culture & Inspection Readiness
Peptide Bioanalysis Using LC-MS/MS: Challenges and Strategies
Phosphoramidite Chemistry: The Engine Behind Oligonucleotide Innovation
Transposase Technologies: Optimizing Cell Line Development for Consistent and High-Yield Biomanufacturing
Regulatory-Ready Nitrosamine Analysis: Advanced LC–MS/MS Solutions for Confident Compliance
Beyond Containment: Innovations in HPAPI Manufacturing for Next-Generation Oncology Therapeutics
Rigorous Toxicology Assessments in Nutraceutical Safety: Meeting FDA and EFSA Guidelines
Nano-Size Engineering Solutions for Poorly Soluble Compounds: A CRDMO Perspective
PROTAC-Based Degrader Antibody Conjugates: Combining Protacs with Monoclonal Antibodies for Precision Therapy
From Molecular Pharmaceutics to Scalable Manufacturing: CRDMO Expertise in Spray Dried Dispersions
Pharmacokinetic Assessment and Anti-Drug Antibodies Assessment of GLP-1 Receptor Agonists
Enhancing Biopharmaceutical Manufacturing with Single-Use Bioreactors: A Transformative Solution for CRDMO Operations
Targeted CNS Drug Delivery: Stereotaxic Animal Model and ICV Administration
A Highly Reproducible
In Vivo
Model for Bleomycin-Induced Lung Fibrosis in Mice to Evaluate Drugs for the Treatment of Idiopathic Pulmonary Fibrosis
A Novel Cell-based Screening Assay for Cholesterol Biosynthetic Pathway Inhibition Using the RapidFire HTMS Platform
Preclinical evaluation of vaccines and antivirals in RSV challenge in BALB/c Mouse models
Preclinical evaluation of vaccines and antivirals in RSV challenge SCID mouse models
Preclinical Evaluation of new Antifibrotics in IPF Rodent Models
Preclinical Evaluation of new Antifibrotics in Corona mouse Virus-Induced Fibrosis Model
Preclinical Evaluation of new Antifibrotics in NASH-Induced Fibrosis Models
Preclinical Evaluation of Vaccines and Antivirals in RSV Challenge Rodent Models
Preclinical Models of Immune oncology for CART-cell Therapeutics Development
Pharmacokinetic Strategies in CNS Drug Discovery
Learn more about our end-to-end capabilities
+
+